GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Emergent BioSolutions Inc (STU:ER4) » Definitions » Other Income (Expense)

Emergent BioSolutions (STU:ER4) Other Income (Expense) : €-419 Mil (TTM As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Emergent BioSolutions Other Income (Expense)?

Emergent BioSolutions's other income expense for the Emergent BioSolutions's pretax income for the three months ended in Mar. 2024 was €-3 Mil. Its other income expense for the trailing twelve months (TTM) ended in Mar. 2024 was €-419 Mil.


Emergent BioSolutions Other Income (Expense) Historical Data

The historical data trend for Emergent BioSolutions's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Emergent BioSolutions Other Income (Expense) Chart

Emergent BioSolutions Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Income (Expense)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.53 3.86 -40.18 -17.37 -405.13

Emergent BioSolutions Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Income (Expense) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.58 -217.27 -208.30 10.09 -3.13

Emergent BioSolutions Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-419 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Emergent BioSolutions  (STU:ER4) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.


Emergent BioSolutions (STU:ER4) Business Description

Traded in Other Exchanges
Address
400 Professional Drive, Suite 400, Gaithersburg, MD, USA, 20879
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company has four main units: vaccines, which produces specialty vaccines for public health threats; devices, such as nasal sprays, skin lotions, and injections; therapeutics, which includes antibody-based treatments; and contract development and manufacturing, which brings treatments to market through collaboration with the pharmaceutical and biotechnology industries and the United States government. Most revenue comes from U.S. government purchases of vaccines, devices, and therapeutic products. The company operates in two reportable segments; the Products Segment and the Services Segment.

Emergent BioSolutions (STU:ER4) Headlines

No Headlines